Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.
The development of human benign or malignant prostatic diseases is closely associated with androgens, primarily testosterone (T) and dihydrotestosterone (DHT). T is converted to DHT by 5-alpha reductase (5-AR) isozymes. Differential expression of 5-AR isozymes is observed in both human benign and malignant prostatic tissues. 5-AR inhibitors (5-ARI) are commonly used for the treatment of benign prostatic hyperplasia (BPH) and were once promoted as chemopreventive agents for prostate cancer (PCa). This review discusses the role of the differential expression of 5-AR in the normal development of the human prostate and in the pathogenesis and progression of BPH and PCa.
Kai
K
Wang
Dong-Dong
DD
Fan
Song
S
Jin
Nian-Zeng
NZ
Xing
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yi-Nong
YN
Niu
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism*; D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D008297:Male; D011467:Prostate / Q000201:enzymology*; D011470:Prostatic Hyperplasia / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000517:prevention & control
D058891:5-alpha Reductase Inhibitors; D007527:Isoenzymes; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase